logo-loader
TechSoftware & services
Instem PLC

Instem CEO delivers corporate presentation

Phil Reason, the chief executive of Instem (LON:INS), provides an insight into the AIM-listed business, which supplies IT applications to companies working on the early phases of developing drugs and chemicals.

It has a robust customer base, with over 400 clients to date serviced by its offices in the US, UK, China and India.

Reason explains how the firm is focusing on market share, client retention, increasing recurring revenue and margin enhancement.

Quick facts: Instem PLC

Price: £3.83

Market: AIM
Market Cap: £62.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem Plc 'very positive about 2017 clinical opportunites'

Instem Plc (LON:INS) said the performance of its clinical arm had further deteriorated since it last updated and will fall “materially short” of its financial targets. The remainder of the business, which provides analytical software to drug developers, has seen “increased...

on 11/23/2016

2 min read